Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRRIT-HFpEF
2024-517448-79-00Phase 3Authorised
- Sponsor
- Region Uppsala
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised trial of spironolactone in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Region Uppsala. Primary endpoint: Incidence rate for total heart failure hospitalizations or cardiovascular death. Planned start Sep 2024; status: authorised.
02
Drugs
spironolactone
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on 2024-517448-79-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517448-79-00.